Juvenile Macular Degeneration (Stargardt Disease) Market Size was valued at USD 1.44 Billion in 2023. The Global Juvenile Macular Degeneration (Stargardt Disease) industry is projected to grow from USD 1.52 Billion in 2024 to USD 1.85 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.36% during the forecast period (2024 - 2032).
Juvenile macular degeneration is a genetic eye disorder that causes progressive vision loss. This disorder affects the retina, the specialized light-sensitive tissue that lines the back of the eye. Specifically, juvenile macular degeneration affects a small area near the center of the retina called the macula. The macula is responsible for sharp central vision, which is needed for detailed tasks such as reading, driving, and recognizing faces. The market is mainly driven by factors such as the increasing prevalence of eye disorders, development of new drugs and therapies, and emerging government policies. However, the high cost of treatment and lack of reimbursement is expected to restrain the growth of this market.
Market Dynamics
The rising prevalence of eye disorder and technological advancements in juvenile macular degeneration are some of the factors that drive the growth of the market. Juvenile macular degeneration is a rare inherited eye condition which affects the central area of the retina called the macula, also known as fundus flavimaculatus. It affects about 1 in 10,000 people and is sometimes called juvenile macular dystrophy since it tends to first appear between the ages of 10 to 20 although visual impairment may not be apparent until as late as ages 30 to 40. Juvenile macular degeneration disease causes parts of the macula to stop working, leading to problems with central vision, detailed vision, and sometimes with color perception. The major driving factors for the global juvenile macular degeneration market are increasing the prevalence of eye disorders, development of new drugs, and therapies, and emerging government policies. However, lack of awareness and no treatment option for juvenile macular dystrophy may hamper the market growth.
Global Juvenile Macular Degeneration (Stargardt Disease) Market Size, by Diagnosis, 2016 and 2027 (USD Million) 
Source: MRFR Analysis
Segmentation
The global juvenile macular degeneration (Stargardt disease) market has been segmented into diagnosis, management, and end user. Based on the diagnosis, the market has been segregated into fluorescein angiography (FA), fundus autofluorescence (FAF), optical coherence tomography (OCT), and electroretinography (ERG). The FA segment accounted for a market value of USD 270.110 million in 2016. Based on management, the market has been segregated into magnifying spectacles, magnifiers, and reading telescopes. The global juvenile macular degeneration (Stargardt disease) market on the basis of end-user is divided into hospital & eye clinics, and research & academic institutes.
Key Players
The prominent players in the global juvenile macular degeneration (Stargardt disease) market are Astellas Pharma Inc (Japan), Sanofi (France), Acucela Inc (Japan), Alkeus Pharma (US), Copernicus Therapeutics (US), Ophthotech Corporation (US), Bayer AG (Germany), Oxford BioMedica PLC (UK), and Grupo Ferrer (Spain).
Some of the key strategies followed by the players operating in the global juvenile macular degeneration (Stargardt disease) market were innovation, product development, acquisition, mergers, and expansion.
Global Juvenile Macular Degeneration (Stargardt Disease) Market Share, by Region, 2016 (%) 
Source: MRFR Analysis
Regional Analysis
The global juvenile macular degeneration (Stargardt disease) market, based on region, is divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
Europe accounted for the significant share in the market for juvenile macular degeneration. Rising investment in research & development, well-developed healthcare infrastructure, and increasing healthcare funds are some of the factors responsible for boosting the growth of the market in this region. Europe held the most significant market share of 32.7 % in 2016.
Americas is estimated to be the second-largest market. This is attributed due to the well-developed technology, rising healthcare expenditure, and the presence of the leading players in the market.
Asia-Pacific is projected to be the fastest-growing market due to the rising aging population, increasing healthcare expenditure, and rapidly changing healthcare sector. In addition to this, improving healthcare facilities and rising economic growth is positively impacting the market growth in this region.
The market in the Middle East & Africa is expected to witness steady growth due to increasing investments in research & development, well-developed infrastructure, and advancement in technology.
Key Updates
Market Segmentation
Global Juvenile Macular Degeneration (Stargardt Disease) Market, by Diagnosis
Global Juvenile Macular Degeneration (Stargardt Disease) Market, by Management
Global Juvenile Macular Degeneration (Stargardt Disease) Market, by End-User
Global Juvenile Macular Degeneration (Stargardt Disease) Market, by Region
Available Additional Customizations
Intended Audience
| Report Attribute/Metric | Details |
| Market Size | 1.85 Billion |
| CAGR | 7.36% |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2021 |
| Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Diagnosis, Management, and End user |
| Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Key Vendors | Astellas Pharma Inc (Japan), Sanofi (France), Acucela Inc (Japan), Alkeus Pharma (US), Copernicus Therapeutics (US), Ophthotech Corporation (US), Bayer AG (Germany), Oxford BioMedica PLC (UK), and Grupo Ferrer (Spain). |
| Key Market Opportunities | Innovation, Product Development, Acquisition, Mergers And Expansion |
| Key Market Drivers | Increasing prevalence of eye disorder and technological advancements in juvenile macular degeneration |
Juvenile Macular Degeneration Market Highlights:
Frequently Asked Questions (FAQ) :
juvenile macular degeneration (stargardt disease) market projected to grow at approximately 6.70% CAGR during the assessment period (2023-2030).
The valuation of the global juvenile macular degeneration (stargardt disease) market is estimated to increase to USD 1.85 Billion by the end of 2032.
Increasing prevalence of eye disorder and technological advancements in juvenile macular degeneration are major tailwinds pushing the growth of the global juvenile macular degeneration (stargardt disease) market.
North America holds the largest share in the global juvenile macular degeneration (stargardt disease) market, followed by Europe and the Asia Pacific, respectively.
Alkeus Pharmaceuticals Inc. (U.S.), Acucela Inc. (U.S.), Astellas Pharma Inc. (Japan), Sanofi (France), ProQR Therapeutics NV (Netherland), Bayer HealthCare (Germany), Copernicus Therapeutics Inc. (U.S.), F. Hoffmann-La Roche (Switzerland), Grupo Ferrer Internacional SA (U.S.), Nemus Bioscience Inc. (U.S.), Iris Pharma (U.S.), Ophthotech Corp (U.S.), Adverum Biotechnologies (U.S.), Iconic Therapeutics (U.S.), PanOptica (U.S.), Neurotech Pharmaceuticals (U.S.), and RXi Pharmaceuticals (U.S.), are some of the top players operating in the global juvenile macular degeneration (stargardt disease) market.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
